Newsroom | 54328 results

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swel...

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics, Inc., the global specialty pharmaceutical business of Tokyo-based Asahi Kasei, with U.S. and European business headquarters in Cary, North Carolina, today announced that the U.S. Food and Drug Administration (FDA) has approved HOVILPRI® (pritelivir) 100 mg tablets for the treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection that is refractory (with or without documented resistance) to treatment with acyclovir, valacy...

MILÁN--(BUSINESS WIRE)--Corcym, una empresa de dispositivos médicos global dedicada a la cirugía cardiaca, anunció hoy que se incluyeron datos positivos a mediano plazo de un subanálisis de su válvula cardíaca aórtica sin sutura Perceval Plus como parte de su ensayo clínico MANTRA en una presentación oral realizada hoy en la reunión anual de la European Association for Cardio-Thoracic Surgery (EACTS). El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducc...

MILAAN--(BUSINESS WIRE)--Corcym, een wereldwijd bedrijf in medische hulpmiddelen dat zich richt op hartchirurgie, heeft vandaag bekendgemaakt dat positieve gegevens op middellange termijn, afkomstig uit een subanalyse van de klinische MANTRA-studie naar de hechtingloze aortaklep Perceval Plus, zijn gepresenteerd tijdens de jaarvergadering van de European Association for Cardio-Thoracic Surgery (EACTS). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als...

MILANO--(BUSINESS WIRE)--Corcym, lo specialista globale dei dispositivi medici cardiochirurgici, oggi ha annunciato la presentazione dei dati positivi a medio termine di una sottoanalisi della sua valvola aortica senza suture Perceval Plus, parte dello studio clinico MANTRA, nel corso della presentazione orale odierna al congresso annuale della European Association for Cardio-Thoracic Surgery (EACTS). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione uffi...

MILAN--(BUSINESS WIRE)--Corcym, une société d’envergure mondiale spécialisée dans les dispositifs médicaux destinés à la chirurgie cardiaque, a annoncé aujourd’hui que les résultats positifs à moyen terme issus d’une sous-analyse de sa valve aortique sans suture Perceval Plus, réalisée dans le cadre de son essai clinique MANTRA, avaient fait aujourd’hui l’objet d’une présentation orale à l’occasion du congrès annuel de l’European Association for Cardio-Thoracic Surgery (EACTS). Cette étude, qui...

MAILAND--(BUSINESS WIRE)--Corcym, ein weltweit tätiges Medizintechnikunternehmen mit Schwerpunkt auf Herzchirurgie, gab heute bekannt, dass positive Zwischenergebnisse aus einer Subanalyse seiner nahtlosen Aortenherzklappe „Perceval Plus“ im Rahmen der klinischen Studie „MANTRA“ heute in einem Vortrag auf der Jahrestagung der European Association for Cardio-Thoracic Surgery (EACTS) vorgestellt wurden. Die Studie ist die längste verfügbare Nachbeobachtungsstudie zu Perceval Plus und der FREE-Gew...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted 2 new employees options to purchase a total of 9,150 shares of the Company’s common stock at an exercise price per share of $23.83, which was the closing pric...